https://prabadinews.com/
  • October 7, 2026
  • Last Update July 17, 2026 9:28 pm
  • United States of America

Tremelimumab–Durvalumab Combo Extends Survival and Improves Cost-Effectiveness Over Sorafenib in Unresectable HCC

Tremelimumab–Durvalumab Combo Extends Survival and Improves Cost-Effectiveness Over Sorafenib in Unresectable HCC

Combination therapy with tremelimumab and durvalumab significantly improves survival in liver cancer patients compared to standard sorafenib treatment.

administrator

Related Articles